We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

103 hedge funds and large institutions have $730M invested in Blueprint Medicines in 2016 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 43 increasing their positions, 20 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

155% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 11

115% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 20

80.56% more ownership

Funds ownership: 0% → 80.56% (+81%)

75% more funds holding in top 10

Funds holding in top 10: 4 → 7 (+3)

29% more capital invested

Capital invested by funds: $567M → $730M (+$163M)

18% more funds holding

Funds holding: 87 → 103 (+16)

58% less call options, than puts

Call options by funds: $378K | Put options by funds: $896K

Holders
103
Holders Change
+16
Holders Change %
+18.39%
% of All Funds
2.58%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.17%
New
28
Increased
43
Reduced
20
Closed
11
Calls
$378K
Puts
$896K
Net Calls
-$518K
Net Calls Change
-$22K

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$49M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$24.1M
3
CAM
Cormorant Asset Management
Massachusetts
+$16.4M
4
BI
BVF Inc
California
+$14.8M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$11.6M

Top Sellers

Rank Fund Capital Flow
1
Fidelity International
Fidelity International
Bermuda
-$11.2M
2
PA
Perceptive Advisors
New York
-$5.61M
3
Victory Capital Management
Victory Capital Management
Texas
-$4.68M
4
SIM
Spark Investment Management
New York
-$2.57M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$6.39M +$1.75M +58,169 +34%
Franklin Resources
27
Franklin Resources
California
$5.61M +$6.03M +200,000 New
JP Morgan Chase
28
JP Morgan Chase
New York
$4.68M +$65.3K +2,168 +1%
Alyeska Investment Group
29
Alyeska Investment Group
Illinois
$2.81M +$3.01M +100,000 New
PI
30
Putnam Investments
Massachusetts
$2.77M – – –
Morgan Stanley
31
Morgan Stanley
New York
$2.65M +$2.57M +85,122 +908%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$2.62M +$228K +7,551 +9%
Goldman Sachs
33
Goldman Sachs
New York
$2.62M +$1.86M +61,672 +195%
SIM
34
Spark Investment Management
New York
$2.58M -$2.57M -85,400 -48%
Charles Schwab
35
Charles Schwab
California
$2.36M +$143K +4,736 +6%
MIM
36
Monashee Investment Management
Massachusetts
$2.24M +$2.41M +80,000 New
BIM
37
BlackRock Investment Management
Delaware
$2.16M -$6.21K -206 -0.3%
Citadel Advisors
38
Citadel Advisors
Florida
$2.1M +$1.69M +56,061 +301%
DCM
39
DAFNA Capital Management
California
$2.03M +$2.19M +72,500 New
Citigroup
40
Citigroup
New York
$1.85M +$1.79M +59,443 +927%
LCM
41
Laurion Capital Management
New York
$1.69M +$1.81M +60,106 New
NC
42
NBW Capital
Massachusetts
$1.67M +$514K +17,062 +40%
TCIM
43
TIAA CREF Investment Management
New York
$1.62M -$169K -5,596 -9%
Tudor Investment Corp
44
Tudor Investment Corp
Connecticut
$1.19M +$999K +33,156 +353%
Swiss National Bank
45
Swiss National Bank
Switzerland
$1.16M +$335K +11,100 +37%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$1.16M -$30.1K -1,000 -2%
D.E. Shaw & Co
47
D.E. Shaw & Co
New York
$1.07M +$450K +14,942 +65%
FP
48
Foundry Partners
Minnesota
$1.05M +$1.13M +37,616 New
Allianz Asset Management
49
Allianz Asset Management
Germany
$1.05M -$148K -4,897 -12%
TA
50
Teachers Advisors
New York
$924K +$26.6K +881 +3%
1
2
3 4 5

BPMC Hedge Fund Activity: Q4 2016 in Review

103 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q4 2016, worth a combined $730M — up 29% from $567M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new BPMC positions and 11 closed out — a net gain of 17 holders — while 43 added to existing stakes and 20 trimmed.

The largest buyer was Deerfield Management, adding an estimated $49M. The largest seller was Fidelity International, cutting an estimated $11.2M.

  • 103 institutional investors held Blueprint Medicines (BPMC) as of Q4 2016, up from 87 in Q3 2016.
  • Funds reported $730M of Blueprint Medicines stock for Q4 2016, up 29% quarter-over-quarter.
  • 28 funds opened new Blueprint Medicines positions in Q4 2016 and 11 closed out, a net change of +17 holders.
  • The largest Blueprint Medicines buyer in Q4 2016 was Deerfield Management, an estimated $49M added.
  • The largest Blueprint Medicines seller in Q4 2016 was Fidelity International, an estimated $11.2M sold.

Based on aggregated 13F filings for Q4 2016.